Navigation Links
Intercell in Medical News

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...r Bavituximab II-60 Jenken to Commence Phase II Trial of JBK-122 II-60 Pevion Biotech Initiates Phase I Study of Hepatitis C Vaccine II-61 intercell Releases Phase II Findings of IC41 II-61 6. Recent Industry Activity II-62 Three Rivers Acquires Infergen(R) II-62 International Consolid...

Intercell Supports the Japanese Encephalitis Vaccination Recommendations of CDC's Advisory Committee on Immunization Practices

...gth of visit ATLANTA, June 24 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced that the U.S. Cente...able in the United States. IXIARO was developed by intercell AG; the rights to market and distribute the vaccin... study with JE-VAX(R). About intercell AG ...

Intercell to Webcast Research & Development Day on Thursday, June 4, 2009

...ENNA and GAITHERSBURG, Md., May 27 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced that it will webcas...tious disease and the primary investigator for the intercell Travelers' Diarrhea Phase II clinical trial. Dr. D...rs. In addition to Dr. DuPont, members of the intercell management team will make presentations including,...

Intercell Executes Multi-Year Contract for Supply of IXIARO(R) to the United States Military

... - Exclusive, multi-year contract executed by intercell and U.S. Department of Defense for purchase of IXI... soon VIENNA, May 8 /PRNewswire-FirstCall/ -- intercell AG (VSE: ICLL; OTC Bulletin Board: INRLY) announce...as follows: Exclusive contract for intercell to supply DLA with all their requirements for JE v...

Intercell Announces FDA Approval of IXIARO(R), a Vaccine Against Japanese Encephalitis

... is a result of an excellent collaboration between intercell and the Walter Reed Army Institute of Research in ...ry VIENNA, March 31 /PRNewswire-FirstCall/ -- intercell AG (VSE: ICLL) today announced FDA approval of its...ant contribution towards development of IXIARO and intercell is very appreciative of this outstanding collabora...

Huntsworth plc Releases Interim Statement on First Quarter 2008

...n. New European clients for Huntsworth Health include Daiichi-Sankyo, Pfizer and Novartis Vaccines, and global accounts won include Roche, Novartis, intercell and Iroko. Our multi-disciplinary business is also increasing, and whilst most clients still offer new projects and pitches in one area (advertising o...

Iomai to Host Conference Call and Webcast Tomorrow, Tuesday, May 13, at 8:30 a.m. EDT

...l/ -- Iomai Corporation (Nasdaq: IOMI ) today said that it will host a conference call and live webcast tomorrow to discuss today's announcement that intercell AG (VSE: ICLL) and Iomai have entered into a definitive agreement pursuant to which Intercell will acquire Iomai for USD 6.60 per share representing a...

Defined Health Announces Final Speaker Roster and Agenda for Therapeutic Insight 2008

...l Development, Genentech * David P. Meeker, MD, President, LSD Therapeutics, Genzyme * Eszter Nagy, MD, PhD, Vice President, Pre-clinical R&D, intercell * Steve J. Offord, PhD, Vice President CNS New Products Marketing, Market Access and Business Development, sanofi-aventis * Carlos Plata-Salam...

Intercell to Begin Phase II JE Vaccine Trials in India

... Austrian biotech major, intercell and its partner Hyderabad-based Biological E. Ltd. announced that they have obtained regulatory clearance to start// a pediatric phase II clinical tri...
Intercell in Medical Technology

Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS

...ENNA and GAITHERSBURG, Md., May 28 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced that it has advance...luenza vaccines," stated Thomas Lingelbach, COO of intercell AG and CEO of intercell USA. "The recent H1N1 influenza situation certainl...

Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine

...orted by PATH VIENNA, April 7 /PRNewswire/ -- intercell AG (VSE: ICLL) announced today that a Phase I clin...ase I trial. Under the terms of the collaboration, intercell will develop the vaccine and make it available at ...is and Otitis media in young children. About intercell AG ...

Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers' Diarrhea Vaccine Study

... WILMINGTON, N.C., Jan. 19 /PRNewswire/ -- intercell AG has retained Inclinix, Inc., to recruit volunte...ginning in April 2009. "We are pleased that intercell AG has chosen Inclinix as their partner for the TD...erious adverse events were reported. About intercell AG ...

USD 12.5 m Funding for the Development of Intercell's Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)

... VIENNA, Austria, Dec. 11 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced the execution of a ...or Intercell's Pandemic Influenza program. intercell is developing a Pandemic Influenza Vaccine Patch S...luenza vaccine, coupled with a single 50-microgram intercell patch was sufficient to provide an immune response...

Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program

... VIENNA, Austria, Sept. 3 /PRNewswire/ -- Today, intercell AG (ICLL) announced the six months follow up data ...sting and future HCV combination treatments. Thus, intercell will follow its development strategy that will als...seen to expand to about EUR 3.5bn by 2006. About intercell AG ...

Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection

... VIENNA, Austria, Aug. 28 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced that its collaborat...based on a conserved protein antigen discovered by intercell and licensed to Merck & Co., Inc. in 2004 on an ex...clinical development, manufacturing and marketing. intercell is eligible to receive milestone payments and roya...

Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine

...el syndrome." As previously announced, Iomai and intercell AG (VSE: ICLL) have entered into an agreement wher...tered into an agreement with Intercell AG in which intercell will acquire Iomai for $6.60 a share. Some matte... to use; that the proposed acquisition of Iomai by intercell does not close or that the companies may be requir...

Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation

... - intercell AG ('Intercell') to acquire Iomai Corporation ('Io...y major shareholders for approximately 1.7 million intercell shares (representing approximately four percent ...chnology in the industry. Through the transaction intercell gains access to a further product ...

Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials

... VIENNA, Austria, May 18, 2007 – intercell AG (VSE, “ICLL”) has been informed by ... increasingly difficult and challenging. About intercell AG: Intercell AG is a growing biotechnology company which focuses on the design and intercell AG is a growing biotechnology company which focus...
Intercell in Biological Technology

Iomai Stockholders Approve Merger With Intercell Subsidiary

GAITHERSBURG, Md., Aug. 1 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI ) announced today that its stockholders approved the merger of Iomai with a wholly-owned subsidiary of Intercell AG. Approximately 71.6 percent of Iomai's outstanding shares entitled to vote at the special mee...

Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today

GAITHERSBURG, Md. and VIENNA, June 19 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI ) announced that its Chief Scientific Officer, Gregory Glenn, M.D., and Alexander Von Gabain, Ph. D., the Chief Scientific Officer of Intercell AG (VSE: ICLL), will speak today at the Biotechnology...

Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis

...December 2008 VIENNA, April 2 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced that its new vaccin... study with JE-VAX(R). About intercell AG intercell AG is an innovative biotechnology company that des...

Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine

... VIENNA, March 31 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced that it will host a...d Thomas Lingelbach (COO and Managing Director intercell Biomedical Ltd., Scotland) Dial-In: Austr... and an operator will then put you through to the intercell conference call. The presentation will be mad...

Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis

... for Q2 2009 VIENNA, March 30 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced that the U.S. Food ...d certain other markets in Asia and Latin America. intercell will directly distribute and market IXIARO to the ... study with JE-VAX(R). About intercell AG ...

Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis

...VIENNA, Austria, Jan. 23 /PRNewswire-FirstCall/ -- intercell AG (VSE: ICLL) today announced that the Australian...egulatory approval for the vaccine in any country. intercell has been successfully advancing parallel regulator...uinea and Pacific Islands (trade name JESPECT(R)). intercell is committed to make JESPECT(R) available to the A...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

... FAES FARMA SA (SIBE Spain: FAE) GPC BIOTECH AG (NASDAQ: GPC ) GRIFOLS SA (SIBE Spain: GRF) H LUNDBECK A/S (OMX Nordic Exchange Copenhagen: LUN) intercell AG (Wiener Bourse, Austria: ICLL) RICHTER GEDEON NYRT (Budapest, Hungary: RICHTBO) STADA ARZNEIMITTEL AG (Frankfurt, Germany: SAZ) ZELTIA SA (SIBE ...

Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis

...technology with regard to the use of certain fusion proteins in the development of a tuberculosis vaccine. The license from SSI includes access to the intercell IC31(R) adjuvant. If the development is successful, sanofi pasteur would manufacture the vaccine commercially. SSI TB vaccine candidates are recombi...
Intercell in Biological Dictionary

Antigens

...n... Information about Antigens in the free online English dictionary and encyclopedia. ... Kirin Brewery Introduces Pneumococcal Antigens from intercell AG, ... by ... The antigens are located on the surface of the red blood cells and the ... in the A+ blood bind the antigens in the B+ blood a...
Other Tags
(Date:4/14/2014)... Henry Ford Hospital reached a medical milestone April ... using a novel way to access the heart. ... the United States performing the unique procedure called ... temporarily connecting major blood vessels. , Northern Michigan ... transcaval procedure on July 3, 2013 when traditional ...
(Date:4/14/2014)... in their radiation treatment decisions leaves cancer patients ... even relieve psychological distress around the experience, researchers ... the University of Pennsylvania report in the ... of 305 patients undergoing radiation treatment, Neha ... department in Radiation Oncology at Penn Medicine, and ...
(Date:4/14/2014)... microRNA 135b, is a vital ,worker, employed by several ... cancers. , Drugs targeted at the microRNA could knock ... while tests for it could identify patients with the ... was carried out by an international team including scientists ... University of Glasgow and Ohio State University in the ...
(Date:4/14/2014)... more evidence that antibiotics can contribute to obesity. ... journal Antimicrobial Agents and Chemotherapy suggests ... and had significant changes in their gut microbiota. ... of Aix-Marseille University, Marseille, France, followed 48 patients ... hydroxychloroquine for Q fever, and 34 control subjects. ...
(Date:4/14/2014)... a decade Chang Lu, associate professor of chemical engineering ... development of tools to efficiently analyze living cells. The ... a range of diseases. , In his lab ... micrometer features for examining molecular events inside cells. These ... studying a low number of cells. , Based on ...
Breaking Medicine News(10 mins):Health News:Henry Ford Hospital hits new heart valve surgery milestone 2Health News:Shared decision making during radiation therapy improves patient satisfaction 2Health News:Shared decision making during radiation therapy improves patient satisfaction 3Health News:'MicroRNA' could be key target for bowel cancer treatment 2Health News:Long-term antibiotic treatment for Q fever causes weight gain 2Health News:Efficient analysis of small quantity of cells improves chances to understand disease 2
(Date:4/16/2014)... to blame for significant baseline levels of arsenic in ... in the Journal of Environmental Quality . , ... of Ohio showed that every single sample had concentrations ... the U.S. Environmental Protection Agency. The findings should not ... regulatory levels typically are set far below those thought ...
(Date:4/15/2014)... and energy for nearly all life on Earth, yet ... example, little is known about how it is regulated ... we do not know the full list of the ... any organism. , , A type of single-cell green ... subject for photosynthesis research. Despite its importance in the ...
(Date:4/15/2014)... Worcester, Mass. Diana Lados, associate professor ... (WPI) and founding director of the university,s ... two major career achievement awards from leading ... in Detroit, SAE International, a global association ... technical experts in the automotive, aerospace, and ...
Breaking Biology News(10 mins):Significant baseline levels of arsenic found in Ohio soils are due to natural processes 2Significant baseline levels of arsenic found in Ohio soils are due to natural processes 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 4WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 2WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 3WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 4WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 5
Other Contents